Get the Stockscreener App
11.32
1.57%
-0.18
After Hours:
11.16
-0.16
-1.41%
Kalvista Pharmaceuticals Inc stock is traded at $11.32, with a volume of 914.08K.
It is down -1.57% in the last 24 hours and down -19.20% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$11.50
Open:
$11.41
24h Volume:
914.08K
Relative Volume:
0.82
Market Cap:
$571.92M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-3.0678
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+3.28%
1M Performance:
-19.20%
6M Performance:
-1.48%
1Y Performance:
-2.67%
1-Day Range:
$11.09
$11.65
1-Week Range:
$10.68
$11.99
52-Week Range:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.32 | 581.02M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
How sentiment analysis helps forecast KalVista Pharmaceuticals Inc.Gap Up & Low Risk Entry Point Guides - newser.com
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsEarnings Growth Report & Community Trade Idea Sharing - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth fundsQuarterly Market Review & Fast Gain Swing Alerts - newser.com
How to track smart money flows in KalVista Pharmaceuticals Inc.July 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
Key resistance and support levels for KalVista Pharmaceuticals Inc.Weekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
What Fibonacci levels say about KalVista Pharmaceuticals Inc. reboundDay Trade & AI Enhanced Execution Alerts - newser.com
KalVista Pharmaceuticals (NASDAQ:KALV) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Can KalVista Pharmaceuticals Inc. stock sustain free cash flow growthGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
KalVista: Prophylaxis Is Shrinking The Acute HAE TAM (NASDAQ:KALV) - Seeking Alpha
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 4%Should You Sell? - MarketBeat
KalVista’s oral HAE treatment shows rapid attack control in European trials - Investing.com
KalVista (KALV) Highlights Game-Changing Oral Treatment for HAE in German Study - GuruFocus
About Us - FinancialContent
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - The Joplin Globe
KalVista Pharmaceuticals Appoints Bilal Arif as COO and Linea Aspesi as CPO - citybiz
Kalvista Pharmaceuticals, Inc. Appoints Bilal Arif as Chief Operating Officer, Effective October 6, 2025 - MarketScreener
KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer - MarketScreener
KalVista Pharmaceuticals appoints new COO and CPO - Investing.com
KalVista Pharmaceuticals appoints new COO and CPO By Investing.com - Investing.com Australia
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer - The Globe and Mail
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
Can momentum traders help lift KalVista Pharmaceuticals Inc.Market Risk Report & Fast Moving Stock Watchlists - newser.com
Tools to assess KalVista Pharmaceuticals Inc.’s risk profileWatch List & Consistent Growth Equity Picks - newser.com
Custom strategy builders for tracking KalVista Pharmaceuticals Inc.Oil Prices & Verified Technical Signals - newser.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
KalVista Pharmaceuticals Appoints Bethany Sensenig to Board - The Globe and Mail
Is KalVista Pharmaceuticals Inc. forming a bottoming base2025 Fundamental Recap & Daily Stock Momentum Reports - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock included in top ETFsWeekly Investment Report & Fast Moving Trade Plans - newser.com
KalVista Pharmaceuticals Appoints Bethany L. Sensenig to Board of Directors - citybiz
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors - BioSpace
KalVista Pharmaceuticals appoints Bethany Sensenig to board of directors By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals appoints Bethany Sensenig to board of directors - Investing.com India
Voya Investment Management LLC Sells 2,151 Shares of KalVista Pharmaceuticals, Inc. $KALV - Defense World
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below 50-Day Moving AverageTime to Sell? - MarketBeat
What drives KalVista Pharmaceuticals Inc 4XC1 stock priceEarnings Per Share Trends & Affordable Trading Strategies - earlytimes.in
KalVista Pharmaceuticals Completes Convertible Notes Sale - TipRanks
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):